Longeveron Inc. 10-Q Summary
Business Context and Reporting Period
Longeveron Inc. is a clinical-stage biotechnology company developing LOMECEL-B cellular therapies for aging-related and life-threatening conditions. Its programs include Aging Frailty, Alzheimer’s disease, metabolic syndrome, acute respiratory distress syndrome and hypoplastic left heart syndrome. The unaudited report covers the three months ended March 31, 2022, compared with the three months ended March 31, 2021.
Financial Performance and Position
| Metric | Q1 2022 | Q1 2021 | Change |
|---|---|---|---|
| Total revenue | $0.37 million | $0.38 million | Down $0.01 million |
| Grant revenue | $0.06 million | $0.21 million | Down 72% |
| Clinical trial revenue | $0.31 million | $0.17 million | Up 88% |
| Cost of revenues | $0.07 million | $0.23 million | Down 69% |
| Gross profit | $0.30 million | $0.15 million | Up 102% |
| Gross margin | Approximately 81% | Approximately 40% | Improved |
| Operating expenses | $3.69 million | $3.61 million | Up 2% |
| Loss from operations | $(3.39) million | $(3.46) million | Improved $0.06 million |
| Net loss | $(3.51) million | $(3.11) million | Worsened $0.40 million |
| Basic and diluted loss per share | $(0.17) | $(0.18) | Improved per share |
| Operating cash flow | $(4.15) million | $(3.03) million | Higher cash use |
- General and administrative expense increased 16% to $1.98 million, primarily from higher compensation and insurance costs.
- Research and development expense increased 6% to $1.43 million, primarily from higher non-grant-reimbursable development costs.
- Selling and marketing expense decreased to $0.29 million from $0.55 million.
- Equity-based compensation decreased to $0.49 million from $1.27 million.
- Other expense was $0.12 million, primarily reflecting an unrealized loss on short-term investments. Q1 2021 included $0.30 million of PPP loan forgiveness.
- Cash and cash equivalents were $22.1 million at March 31, 2022, compared with $25.7 million at December 31, 2021. Short-term investments were $8.45 million, and reported working capital was approximately $29.5 million.
- Total liabilities were $4.87 million, consisting primarily of operating lease liabilities. The filing reports no credit facility or committed debt financing.
- Accumulated deficit was $47.4 million, and total stockholders’ equity was $34.3 million.
- Cash used in operations was partly offset by $0.77 million of investing cash flow, primarily from sales of short-term investments. Financing cash use was $0.14 million for taxes related to vested RSUs.
Material Changes Versus the Prior Comparable Period
- Revenue was essentially flat, but the mix shifted from grants toward clinical trial revenue. Management attributed the clinical trial increase to reduced COVID-19 travel restrictions affecting the Bahamas Registry Trial.
- Lower grant activity reflected completion of grant-funded clinical trials and reduced available grant funding.
- Gross profit more than doubled because of lower grant and Bahamas Registry Trial costs.
- Despite improved operating loss, net loss increased because Q1 2021 benefited from PPP loan forgiveness and other income, while Q1 2022 recorded investment-related losses.
- Operating cash use increased by $1.12 million, primarily due to the higher net loss and approximately $0.9 million of prepaid insurance expenses.
- During the quarter, 117,772 Class B shares were converted into Class A shares. The company also granted 106,825 stock options and had 410,075 options outstanding at March 31, 2022.
Guidance, Outlook, Risks and Unusual Items
- Management stated that cash, cash equivalents and investments at March 31, 2022 were expected to fund operating expenses and capital requirements for at least the next 12 months, and elsewhere estimated funding through the first half of 2024. These estimates depend on assumptions that may prove inaccurate.
- The company expects continuing operating losses and increasing research, clinical, manufacturing, intellectual property and public-company costs. Additional capital will likely be required through equity, debt, grants, collaborations, licensing or other financing.
- Clinical programs advanced during the quarter, including the Phase 2a Alzheimer’s trial, continued enrollment in the ELPIS II HLHS trial, planned initiation of the Japanese Aging Frailty trial and continued screening in the ARDS trial.
- Management expected HERA Aging Frailty top-line results in the first half of 2022 and the Japanese Aging Frailty trial to begin in the first half of 2022. The filing does not provide later outcomes.
- COVID-19 continued to create risks involving clinical follow-up, enrollment, travel, manufacturing, supply chains and regulatory timelines. Missed visits or subject dropouts could affect trial results or require a trial to be restarted.
- A securities class action lawsuit alleges materially false or misleading statements in IPO materials and subsequent disclosures. The company disputes the allegations; potential losses could not be estimated.
- As of March 31, 2022, the company reported approximately $3.0 million of operating lease obligations and $3.6 million of expected clinical research organization expenditures over the next two years. Additional milestone and royalty obligations may arise, including under licensing agreements.
- Subsequent events included the appointment of K. Chris Min as Chief Medical Officer on April 4, 2022, and the announcement that CEO Geoff Green would step down effective June 1, 2022. Dr. Min was appointed interim CEO.
Important Facts for Investors to Verify
- Whether the company’s cash runway assumptions remain valid given quarterly operating cash use of $4.15 million and expected increases in development spending.
- Enrollment, timing and clinical results for the Alzheimer’s, HLHS, Aging Frailty and ARDS programs, including the impact of COVID-19-related disruptions.
- The sustainability and composition of revenue, particularly dependence on the Bahamas Registry Trial, grants and contract-related activities rather than approved product sales.
- The status, potential exposure and insurance coverage associated with the securities class action lawsuit.
- Potential dilution from outstanding options, warrants and future equity financing; the filing excluded approximately 1.88 million potentially dilutive instruments from Q1 2022 diluted loss per share.
- Management’s transition following the CEO’s planned departure and the company’s ability to recruit a permanent successor.